XENE
Xenon Pharmaceuticals Inc
36.60$
-2.7%
vs. previous close
Closing price · As of: Oct 6, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -197.9% | 318.5% | -12.1% | 0.9% | -116.2% | -1,085.2% | -9,236.7% | – | -67.8% | -149.6% | -377.0% | -1,043.4% | – | – | -3,721.6% | |
| 16.4% | 5.5% | 2.6% | 2.6% | 6.7% | 47.9% | 208.7% | – | 6.3% | 2.0% | 4.9% | 17.2% | – | – | 33.9% | |
| 6.5% | 2.9% | 2.4% | 2.7% | 23.9% | 119.9% | 719.0% | – | 42.8% | 17.6% | 54.3% | 216.0% | – | – | 716.1% | |
| – | – | 2.3% | 2.7% | 67.8% | 44.3% | 245.0% | – | 36.4% | 18.5% | 60.3% | 244.4% | – | – | – | |
| -47.2% | 331.4% | -61.0% | -50.3% | -89.6% | 98.1% | 178.8% | – | 490.8% | -81.1% | -14.4% | -7.2% | – | – | 58.1% | |
| 4.2% | 3.7% | 0.6% | 5.4% | 3.5% | 15.5% | 101.3% | – | 18.2% | 8.2% | 11.1% | 30.7% | – | – | 10.7% | |
| 200.8% | 3.4% | -41.9% | -11.4% | 65.4% | -2,653.5% | 7,811.6% | – | -970.7% | -52.3% | -1,338.4% | -3,137.6% | – | – | 2,906.6% | |
| – | – | – | 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| – | – | 0.2% | 150.4% | 1.8% | 1,329.1% | 56.9% | – | 403.0% | 318.8% | 1.4% | 7.5% | – | – | – | |
| – | – | -6.2% | 24.3% | 44.3% | 382.3% | 2,216.4% | – | -245.2% | -52.1% | 0.0% | 0.0% | – | – | – | |
| 0.0% | – | -16.1% | 145.0% | 1.8% | 1,329.1% | 2,273.3% | – | 403.0% | 266.7% | 2,427.4% | 2,951.8% | – | – | 1,561.5% | |
| -1.6% | 323.1% | -81.2% | 120.1% | -85.9% | -2,304.8% | 1,090.4% | – | -629.7% | 63.0% | 708.8% | -1,255.5% | – | – | 752.7% | |
| -202.1% | 314.8% | -12.7% | -4.5% | -119.8% | -1,100.7% | -9,337.9% | – | -86.0% | -157.8% | -388.1% | -1,074.0% | – | – | -3,732.2% |
Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.